| Latest Forum Topics / DISA Last:0.001 -- |
 Post Reply
|
|
20 for 1 bonus warrant issue
|
|||
|
HuatAh7898
Elite |
23-Mar-2026 08:50
|
||
|
x 1
x 0 Alert Admin |
coming to a theater soon | ||
| Useful To Me Not Useful To Me | |||
|
sklong138
Elite |
23-Mar-2026 07:45
|
||
|
x 0
x 0 Alert Admin |
Here is a concise summary of the announcement, highlighting the key points for stakeholders:
---
Summary of Announcement
Company: DISA Limited (the " Company" )
Date: 23 March 2026
Event: Proposed disposal and subscription of shares in its subsidiary, Advance Digital Healthcare Pte. Ltd. (" ADH" ), to a third party, Mr. Meng Fanbing.
1. The Transactions
The Company has entered into a tripartite agreement involving:
· Proposed Disposal: DISA will sell a 7.58% stake in ADH to Mr. Meng for S$1,000,000.
· Proposed Subscription: ADH will issue new shares representing a 5.753% stake to Mr. Meng for another S$1,000,000.
Total Consideration from Mr. Meng: S$2,000,000 (with a non-refundable deposit of S$50,000 already paid).
2. Impact on Ownership
· Before: DISA owned 100% of ADH.
· After: DISA will own 87.392% , and Mr. Meng will own 12.608%.
3. Rationale
· For DISA: Unlocks value from its investment and strengthens its cash position.
· For ADH: Gains a capital injection to fund growth and expansion, while benefiting from the strategic participation of an experienced entrepreneur.
4. Key Financial Effects
· No Profit or Loss Recognized: Since DISA retains control, the disposal will be recorded as an equity transaction. The S$1 million consideration will result in a **S$745,000 increase directly in equity**.
· Net Tangible Assets (NTA): Pro-forma NTA per share is expected to increase from 0.027 cents to 0.037 cents.
· Loss Per Share: No impact, as the transaction will not affect the profit or loss statement.
5. Regulatory Classification
· The transaction is classified as a " discloseable transaction" under Catalist Rules.
· No Shareholder Approval Required: The disposal does not meet the 20% threshold for a " principal subsidiary" under Rule 805, and the relative figures fall within the limits that do not mandate a shareholder vote.
6. Important Points for Stakeholders
· Preservation of Control: DISA maintains a strong controlling stake (87.392%) in ADH.
· Cash Inflow: The Group receives S$2 million in cash (S$1 million for the sale and S$1 million via subscription into ADH).
· Strategic Partnership: The new shareholder is an unrelated third party with extensive business experience, expected to contribute positively to ADH&rsquo s growth.
· Execution Risk: Completion is scheduled for 2 June 2026 and is subject to conditions in the agreement. If completion does not occur, the S$50,000 deposit is forfeited.
· Caution: Shareholders are advised to exercise caution when dealing in the Company&rsquo s shares until the transaction is completed.
|
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
newbie1118
Master |
01-Dec-2025 13:04
|
||
|
x 0
x 0 Alert Admin |
D End? | ||
| Useful To Me Not Useful To Me | |||
|
bishalnb
Master |
21-Nov-2025 11:40
|
||
|
x 0
x 0 Alert Admin |
DISA builds, ... a whisper turning loud, A pulse within the striving crowd The climb grows steep, yet onward swings, Where fervent hope on courage clings. Each gear engaged, the summit nears, Through winding doubt and passing fears And ever higher, breathless, bright It gears towards the piercing light. 
|
||
| Useful To Me Not Useful To Me | |||
|
sklong138
Elite |
20-Nov-2025 20:20
|
||
|
x 0
x 0 Alert Admin |
Investment Assessment: DISA Limited (DISA SP)
Overall Sentiment: Cautiously Optimistic. This development is a clear positive step in the right direction, validating the company' s strategy and opening a tangible path to growth. However, it remains in the trial phase, and the ultimate financial impact is still future-dependent.
---
Key Benefits to Shareholders:
1. Market Validation and De-Risking:
· Proven Track Record: The trial follows a successful deployment at National University Hospital (NUH), which demonstrated " improvements in workflow efficiency, and reduction in patient wait times." This is not a speculative product it has a track record within Singapore' s reputable healthcare system. This reduces the technology risk for shareholders.
· Independent Validation: The trial is at Ng Teng Fong General Hospital (NTFGH), an " independent acute hospital." Success here proves the device' s utility is not limited to a single institution, strengthening the investment thesis and making the technology more attractive to other hospitals.
2. Expansion into a Lucrative New Market Segment:
· Strategic Pivot: The announcement explicitly states this " directly opens up a new market segment... beyond tertiary specialist centres." This is significant. Moving from specialized ophthalmology centres to high-volume community and general hospitals dramatically expands the Total Addressable Market (TAM). The " immense demand for ophthalmological services in mainstream healthcare settings" represents a much larger and more sustainable revenue opportunity.
3. Clear Path to Monetization and Recurring Revenue:
· CEO' s Direct Statement: The CEO, Eddie Chng, explicitly mentions " creating a recurring revenue stream." This is a key term for investors. It suggests a business model beyond one-off device sales, potentially including subscription fees for software, maintenance, or consumables. Recurring revenue models are highly valued by the market as they provide predictable, stable cash flows and enhance company valuations.
4. Operational and Financial Benefits:
· Scalability: The device " frees up valuable time for healthcare professionals, enabling clinics to manage higher patient volumes and reduce operational costs." This is the core value proposition that hospitals will pay for. A successful trial at NTFGH demonstrates scalability, a critical factor for the Group to grow its revenue without a linear increase in costs.
· Strong R& D Focus: The release reinforces the Group' s " strong in-house R& D capabilities," which is a positive signal for long-term shareholders, indicating a pipeline of future innovations and a commitment to maintaining a competitive edge.
Risks and Considerations for Shareholders:
· Trial Outcome: The primary risk is that the four-month trial does not meet NTFGH' s expectations. While the NUH success is encouraging, failure here could delay expansion plans and damage credibility.
· Commercialization Timeline: Even a successful trial does not guarantee an immediate, large-scale purchase order. The process from a successful pilot to a widespread, revenue-generating rollout can be slow in the public healthcare sector.
· Financial Impact Not Quantified: The release does not provide any financial figures. The size of the potential contract, profit margins, or the expected contribution to earnings are unknown. Without this, it is difficult to quantify the near-term financial impact.
· Competitive Landscape: The announcement does not mention competitors. It is crucial to assess if DISA' s AVAT device has a sustainable competitive advantage (e.g., through its " proprietary optics" ) or if other companies could develop similar solutions.
Investment Conclusion:
For shareholders, this news is a strong positive catalyst that reinforces the long-term growth narrative of DISA.
· For existing shareholders: This announcement validates the investment thesis. It demonstrates execution on strategy and provides a tangible milestone for future growth. It is a reason to hold the stock with increased confidence.
· For potential investors: This development makes DISA more attractive. It shows the company is moving beyond R& D into commercial deployment and market expansion. However, given the Catalist listing and the early stage of commercialization, it should be considered a speculative growth stock. Investment should be sized accordingly.
Next Key Catalysts to Watch For:
1. The outcome of the four-month trial at NTFGH (expected around Q1 2026).
2. Any announcement of a follow-on purchase order from NTFGH or another hospital.
3. Financial results that begin to show material revenue contribution from the AVAT segment.
In summary, this news significantly enhances DISA' s prospects by de-risking the technology and charting a clear course for market expansion and recurring revenue, which are fundamental drivers of shareholder value.
|
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
benlwl
Member |
01-Oct-2025 11:10
|
||
|
x 0
x 0 Alert Admin |
Personal assumption. Investor losing interest.. I think they bought @ 0.001 and hoping it a multi-bagger but after long wait, decided to sell it.. losing brokerage fees? There will be other investors doing the same and hope for the time to ripe.
|
||
| Useful To Me Not Useful To Me | |||
|
Eatall
Veteran |
01-Oct-2025 10:59
|
||
|
x 0
x 0 Alert Admin |
What had happened to DISA? | ||
| Useful To Me Not Useful To Me | |||